Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $7.52 million. The enterprise value is $5.86 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 7.75 million shares outstanding. The number of shares has increased by 212.14% in one year.
| Current Share Class | 7.75M |
| Shares Outstanding | 7.75M |
| Shares Change (YoY) | +212.14% |
| Shares Change (QoQ) | +13.41% |
| Owned by Insiders (%) | 13.72% |
| Owned by Institutions (%) | 12.80% |
| Float | 5.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.12 |
| Forward PS | 0.17 |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.53 |
| Quick Ratio | 0.70 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.48 |
Financial Efficiency
Return on equity (ROE) is -390.90% and return on invested capital (ROIC) is -233.27%.
| Return on Equity (ROE) | -390.90% |
| Return on Assets (ROA) | -46.00% |
| Return on Capital (ROIC) | -233.27% |
| Revenue Per Employee | $415,976 |
| Profits Per Employee | -$151,024 |
| Employee Count | 85 |
| Asset Turnover | 1.34 |
| Inventory Turnover | 1.66 |
Taxes
In the past 12 months, Biofrontera has paid $19,000 in taxes.
| Income Tax | 19,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.00% in the last 52 weeks. The beta is 0.39, so Biofrontera's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -76.00% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 1.16 |
| Relative Strength Index (RSI) | 49.97 |
| Average Volume (20 Days) | 1,156,575 |
Short Selling Information
The latest short interest is 316,572, so 4.09% of the outstanding shares have been sold short.
| Short Interest | 316,572 |
| Short Previous Month | 457,119 |
| Short % of Shares Out | 4.09% |
| Short % of Float | 6.09% |
| Short Ratio (days to cover) | 0.08 |
Income Statement
In the last 12 months, Biofrontera had revenue of $35.36 million and -$12.84 million in losses. Loss per share was -$3.08.
| Revenue | 35.36M |
| Gross Profit | 16.66M |
| Operating Income | -19.36M |
| Pretax Income | -23.08M |
| Net Income | -12.84M |
| EBITDA | -18.85M |
| EBIT | -19.36M |
| Loss Per Share | -$3.08 |
Full Income StatementBalance Sheet
The company has $2.88 million in cash and $994,000 in debt, giving a net cash position of $1.89 million or $0.24 per share.
| Cash & Cash Equivalents | 2.88M |
| Total Debt | 994,000 |
| Net Cash | 1.89M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 5.53M |
| Book Value Per Share | 0.85 |
| Working Capital | 5.90M |
Full Balance SheetCash Flow
| Operating Cash Flow | -18.12M |
| Capital Expenditures | n/a |
| Free Cash Flow | -18.12M |
| FCF Per Share | -$2.34 |
Full Cash Flow StatementMargins
Gross margin is 47.10%, with operating and profit margins of -54.76% and -36.31%.
| Gross Margin | 47.10% |
| Operating Margin | -54.76% |
| Pretax Margin | -36.25% |
| Profit Margin | -36.31% |
| EBITDA Margin | -53.31% |
| EBIT Margin | -54.76% |
| FCF Margin | -73.92% |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -212.14% |
| Shareholder Yield | -212.14% |
| Earnings Yield | -165.66% |
| FCF Yield | -233.82% |
Analyst Forecast
The average price target for Biofrontera is $7.00, which is 621.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 621.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 26.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
Biofrontera has an Altman Z-Score of -9.66 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.66 |
| Piotroski F-Score | 2 |